Page 1

OptiScan Imaging Limited ABN 81 077 771 987 ASX Announcement 29 April 2021 APPENDIX 4C QUARTERLY ACTIVITIES & CASHFLOW REPORT QUARTER ENDED 31 MARCH 2021 Melbourne , Australia , 29 April 2021 : Australian medical technology company Optiscan Imaging Limited ( ASX : OIL ) ( OptiScan or the Company ) , a leader in medical technology using confocal laser endomicroscopy , is pleased to release its Appendix 4C - Quarterly Cashflow report and business update for the quarter ended 31 March 2021 ( Quarter ) . All financial results are in Australian dollars and are unaudited . Highlights for the Quarter • • Commenced stage three of the Breast Cancer Surgical Margin Assessment Trial at Royal Melbourne Hospital , Frances Perry House and Epworth Hospital , led by Professor Bruce Mann , Director of Breast Cancer Services for the Royal Melbourne Hospital and Royal Women's Hospital and Professor of Surgery at The University of Melbourne . Commenced imaging of patients at the University of Melbourne's Melbourne Dental School ( MDS ) trial and continued the fluorescein dosing study required for the application for OptiScan's FDA 510 ( k ) clearance to market the device in the United States . • Continued third party independent testing and conducted validation and verification activities for the InVivage ™ clinical device required to prepare the application for US FDA 510 ( k ) clearance . • • • . Sales orders from Carl Zeiss Meditec AG ( CZM ) of approximately $ 350k . Awarded Federal Government Entrepreneurs ' Programme - Growth Grant with matched funding of $ 20k to support the engagement of expert advisers for the development of a United States market entry strategy for InVivage ™ . Engaged a former leading US based medical executive and oral surgeon to assist with the strategy . Appointment of Mr Ron Song as a non - executive Director . Total Cash Flows of $ 154k for the Quarter with Cash Flows from Operating Activities of ( $ 903k ) for the Quarter and ( $ 1,080k ) for the 9 months to 31 March 2021 . Developments Post End of Quarter • Appointment of Mr Robert Cooke as non - executive Chair and Darren Lurie as Managing Director . Breast Cancer Surgical Margin Assessment Trial ( Breast Trial ) OptiScan commenced stage three of its Breast Cancer Surgical Margin Assessment Trial in Melbourne at Royal Melbourne Hospital , Frances Perry House and Epworth Hospital . The study led by Professor Bruce Mann , Director of Breast Cancer Services for the Royal Melbourne Hospital and Royal Women's Hospital , and a Professor of Surgery at The University of Melbourne will involve 20 breast cancer patients using OptiScan`s FIVE2 ( ViewnVivo ) endomicroscope . Funding for the study is supported by the Medical Device Partnering Program grant . Phone ( 613 ) 9538 3333 Website www.OptiScan.com PO Box 1066 , Mt Waverley MDC VIC 3149 Australia